PMID- 31906956
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20200615
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jan 6
TI  - Crizotinib-induced osteitis mimicking bone metastasis in a stage IV 
      ALK-rearranged NSCLC patient: a case report.
PG  - 14
LID - 10.1186/s12885-019-6486-3 [doi]
LID - 14
AB  - BACKGROUND: Targeted therapies are a standard of care for first-line treatment of 
      Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). 
      Giving the rapid pace of drug discovery and development in this area, reporting 
      of adverse effects of ALK inhibitors is crucial. Here, we report a case of 
      osteitis induced by an ALK inhibitor mimicking bone metastasis, a previously 
      undescribed side effect of crizotinib. CASE PRESENTATION: A 31-year-old woman 
      with stage IV ALK-rearranged NSCLC presented with back pain after 3 months of 
      crizotinib treatment. Diagnostic work-up showed osteitis on the 4th and 5th 
      thoracic vertebrae, anterior soft tissue infiltration and epiduritis, without any 
      sign of infection. Spinal cord decompression, histological removal and 
      osteosynthesis were performed. Histologic examination showed necrosis with 
      abundant peripheral neutrophils, no microorganism nor malignant cell. Symptoms 
      and Computarized Tomography-abnormalities rapidly diseappeared after crizotinib 
      withdrawal and did not recur after ceritinib onset. CONCLUSIONS: This is the 
      first report of crizotinib-induced osteitis. Crizotinib differs from other ALK 
      inhibitors as it targets other kinases as well, which may have been responsible 
      for the osteitis. Crizotinib can induce rapidly extensive osteitis, which can 
      mimic tumor progression.
FAU - Guisier, F
AU  - Guisier F
AUID- ORCID: 0000-0002-8166-7303
AD  - Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, 
      CHU Charles Nicolle, Rouen, France. florian.guisier@chu-rouen.fr.
AD  - LITIS QuantIF EA4108, Normadie Univ, Rouen, France. florian.guisier@chu-rouen.fr.
AD  - INSERM CIC 1404, CHU Charles Nicolle, Rouen, France. 
      florian.guisier@chu-rouen.fr.
FAU - Piton, N
AU  - Piton N
AD  - Service d'anatomie et cytologie pathologiques, CHU Charles Nicolle, Rouen, 
      France.
FAU - Bellefleur, M
AU  - Bellefleur M
AD  - Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, 
      CHU Charles Nicolle, Rouen, France.
FAU - Delberghe, N
AU  - Delberghe N
AD  - Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, 
      CHU Charles Nicolle, Rouen, France.
FAU - Avenel, G
AU  - Avenel G
AD  - Service de rhumatologie, CHU Charles Nicolle, Rouen, France.
FAU - Angot, E
AU  - Angot E
AD  - Service d'anatomie et cytologie pathologiques, CHU Charles Nicolle, Rouen, 
      France.
FAU - Vittecoq, O
AU  - Vittecoq O
AD  - Service de rhumatologie, CHU Charles Nicolle, Rouen, France.
FAU - Ould-Slimane, M
AU  - Ould-Slimane M
AD  - Service d'orthopedie et traumatologie, CHU Charles Nicolle, Rouen, France.
FAU - Morisse-Pradier, H
AU  - Morisse-Pradier H
AD  - Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, 
      CHU Charles Nicolle, Rouen, France.
FAU - Salaun, M
AU  - Salaun M
AD  - Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, 
      CHU Charles Nicolle, Rouen, France.
AD  - LITIS QuantIF EA4108, Normadie Univ, Rouen, France.
AD  - INSERM CIC 1404, CHU Charles Nicolle, Rouen, France.
FAU - Thiberville, L
AU  - Thiberville L
AD  - Service de pneumologie, oncologie thoracique et soins intensifs respiratoires, 
      CHU Charles Nicolle, Rouen, France.
AD  - LITIS QuantIF EA4108, Normadie Univ, Rouen, France.
AD  - INSERM CIC 1404, CHU Charles Nicolle, Rouen, France.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200106
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfones)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - K418KG2GET (ceritinib)
SB  - IM
MH  - Adult
MH  - Anaplastic Lymphoma Kinase/*antagonists & inhibitors/genetics
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Bone Neoplasms/diagnosis/secondary
MH  - Carcinoma, Non-Small-Cell Lung/complications/*drug therapy/genetics/pathology
MH  - Crizotinib/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/complications/*drug therapy/genetics/pathology
MH  - Osteitis/*chemically induced/diagnostic imaging/pathology
MH  - Protein Kinase Inhibitors/*adverse effects/pharmacology
MH  - Pyrimidines/pharmacology
MH  - Sulfones/pharmacology
MH  - Tomography, X-Ray Computed
PMC - PMC6945627
OTO - NOTNLM
OT  - ALK inhibitors
OT  - ALK-rearranged NSCLC
OT  - Ceritinib
OT  - Crizotinib
OT  - Drug toxicity
OT  - Osteitis
COIS- FG reports personal fees BMS, MSD/MERCK US, ASTRA ZENECA, BOEHRINGER INGELHEIM 
      and ROCHE, and non-financial support from BMS, BOEHRINGER INGELHEIM, CHUGAI and 
      PFIZER, outside the submitted work. NP, MB, ND, GA, EA, OV, MOS, HMP, MS and LT 
      have nothing to disclose.
EDAT- 2020/01/08 06:00
MHDA- 2020/06/17 06:00
PMCR- 2020/01/06
CRDT- 2020/01/08 06:00
PHST- 2019/03/08 00:00 [received]
PHST- 2019/12/20 00:00 [accepted]
PHST- 2020/01/08 06:00 [entrez]
PHST- 2020/01/08 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/01/06 00:00 [pmc-release]
AID - 10.1186/s12885-019-6486-3 [pii]
AID - 6486 [pii]
AID - 10.1186/s12885-019-6486-3 [doi]
PST - epublish
SO  - BMC Cancer. 2020 Jan 6;20(1):14. doi: 10.1186/s12885-019-6486-3.